top of page
#WCIRDC
Lawrence J. Mandarino, PhD
Insulin Resistance in T2DM Molecular and Clinical Considerations
Philipp Scherer, PhD
Fat/Adipocytes and Insulin Resistance
Ralph A. DeFronzo, MD
Insulin Resistance and Cardiovascular Disease
Steven Kahn, MD
Insulin Resistance, Insulin Secretion, Insulin Clearance: Who is the Culprit?
Karol Watson, MD, PhD
Racial Health Disparities in Cardiovascular Disease During the COVID-19 Pandemic
Tracey McLaughin, MD
Obesity and Insulin Resistance in Acute and Long Covid
Pam Taub, MD
Cardiovascular Sequelae of COVID-19 in Adults – ACC Experts Pathway
John P. Kirwan, MSc, PhD
Targeting Sarcopenic Obesity to Mitigate Risk of Cardiovascular Disease
Christos Mantzoros, MD, PhD
Leadership in Addressing Unmet Clinical Needs in Metabolism- an American Odyssey From the Bedside to Nucleoside and Back
Jonathan E. Campbell, PhD
Fused Incretins - Mechanisms of Action
George Grunberger, MD
ADA-EASD Consensus Management of Hyperglycemia
Biykem Bozkurt, MD, PhD
Guideline Directed Management of Heart Failure
Stephen Greene, MD
The Intersection of CKD and HF
Luigi Gnudi, MD, PhD
Glucose is not always sweet: Mechanisms, Presentation & Treatments of DM Co-Morbidities
Friday, December 2, 2022
Sonia Caprio, MD
Mechanistic Insight Into the Heterogeneity of Glucose Response in Youth with Obesity
Alan Sinaiko, MD
Childhood Cardiovascular & DM Risks leading to Adult Diabetes & Cardiovascular Events
Peter J. Grant, MD
Microvascular Disease: The Wrong Targets?
​Erin Michos, MD
Lipids in Women Across the Lifespan
Erin Michos, MD
CKD in Diabetes-Prevalence, Pathophysiology Impact on Cardiometabolic Diseases
Matthew Weir, MD
Diagnosing DKD- Screening, Methodology Role of Guidelines
Peter Rossing, MD, DMSc
New Treatment Paradigm of DKD the Role of Non-Steroidal MRA
Saturday, December 3, 2022
Matthew Weir, MD
Obesity and Dysmetabolism as Risk Factors for CKD
Michelle Van Name, MD
The Role of Non Insulin Interventions in T1D
Max Petersen MD, PhD
Clinical Efficacy of Time Restricted Eating in People: Hope or Hype?
Eduardo Grunvald, MD
Managing Obesity Circa 2022 - The New & the Newer
Christian Mende, MD
Hypertension/Kidney
Naomi M. Hamburg, MD
Contemporary Management of Peripheral Artery Disease
Jane Parnes, MD
Late Breaking: A Phase 1 Study of AMG 133 in Subjects with Obesity
Paul Franks, MD,PhD
Heterogeinity of Type 2 Diabetes Phenotypes
Jorge Plutzky, MD
Remote, Algorithmic Management of Cardio-Metabolic Disorders at Scale: Disrupting Medicine?
Mikhail Kosiborod, MD
Cardiometabolic Alliance Patient-Level Registry Data
Matthew Budoff, MD
CKD 3 as CV Risk Equivalent
Norman E. Lepor, MD, FACC
Remnant Lipoproteins: The Rediscovered CVD Risk Factor
Shivani Misra, MD
Epidemiology of Diabetes and Clinical Characteristics
bottom of page